-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26

Benzinga·03/24/2026 17:23:46
Listen to the news
Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.